LB Pharmaceuticals initiates coverage with buy rating; target price $65
LBRX•Canaccord Genuity initiated coverage of LB Pharmaceuticals with a buy rating and a $65 target price.
Related News
TIM updates financial events calendar for 2026
TIMB•
Bank Raya names Hari Basuki director, replacing Kicky Andrie Davetra
AGRO•
UBS cuts Regency Centers' target price to $77 from $85
REG•
Moderna: BofA Global Research raises price objective to $200 from $170
MRNA•
Oil eases, breadth improves as US stocks rise
SPY•